| Drug | Tier | Fit Score | Addressable Undiagnosed (USA) | Ada Revenue Opportunity (USA, 5% Capture) |
|---|---|---|---|---|
| TAKHZYRO Hereditary angioedema |
Tier 1 | 9/10 | 1,500 - 6,300 | $1.3M - $12.1M |
| ENTYVIO IBD (UC, CD) |
Tier 1 | 8/10 | 25,000 - 85,000 | $2.8M - $27.5M |
| EOHILIA Eosinophilic esophagitis |
Tier 1 | 8/10 | 40,000 - 115,000 | $1.4M - $9.3M |
| Immunoglobulins PIDD, CIDP |
Tier 2 | 7/10 | 19,000 - 116,000 | $3.8M - $94.0M |
| NINLARO Multiple myeloma |
Tier 3 | 5/10 | 100 - 450 | $240K - $3.2M |
| ADCETRIS Hodgkin lymphoma |
Tier 3 | 4/10 | 50 - 200 | $120K - $1.8M |
| LIVTENCITY Post-transplant CMV |
NO | 3/10 | N/A (specialist-driven) | N/A |
| QDENGA Dengue vaccine |
NO | 2/10 | N/A (preventive) | N/A |
| ADZYNMA Congenital TTP |
NO | 3/10 | 10 - 50 (ultra-rare) | <$1M |
| VYVANSE ADHD (generic) |
NO | N/A | N/A (generic erosion) | N/A |
Indication: Hereditary Angioedema (HAE)
2.6-11 years globally; Germany average 12.6 years; up to 40+ years in extreme cases. During this time, patients face life-threatening laryngeal edema, debilitating abdominal attacks misdiagnosed as appendicitis/IBS, and unpredictable swelling disrupting daily life.
| Market | Addressable Undiagnosed | Net Revenue per Patient | Ada Opportunity (5% capture) |
|---|---|---|---|
| USA | 1,500 - 6,300 | $213,595 - $320,393 / year | $1.3M - $12.1M / year |
| DACH (Germany, Austria, Switzerland) | 100 - 400 | $240,000 - $365,000 / year | $96K - $876K / year |
| Rest of World | 5,000 - 15,000 | $100,000 - $200,000 / year | $2M - $18M / year |
| TOTAL | 6,600 - 21,700 | - | $3.4M - $31M / year |
"HAE's Silent Decade: Up to 12.6 Years from First Swelling to Diagnosis"
Hereditary angioedema (HAE) patients endure a median 2.6 to 11 years of diagnostic odyssey—cycling through emergency rooms, allergists, and gastroenterologists—before a simple blood test confirms their genetic disease. In Germany, the average delay is 12.6 years, with some patients waiting over 40 years. During this time, patients face life-threatening laryngeal edema (airway swelling), debilitating abdominal attacks misdiagnosed as appendicitis or IBS, and unpredictable facial/limb swelling that disrupts daily life.
The diagnostic clue? Angioedema without urticaria (hives)—a red flag missed by 70% of primary care encounters. Ada's AI assessment immediately escalates recurrent non-urticarial swelling for C1-INH testing, cutting diagnosis time from years to weeks. With 30-50% of HAE cases undiagnosed globally (~1,500-6,300 patients in the US alone), and TAKHZYRO commanding a market-leading $213,595-$320,393 net annual revenue per patient, the Ada Patient Finder opportunity reaches $1.3M-$12.1M in first-year US revenue alone at 5% capture (8-12% finder fees)—while saving lives from preventable laryngeal edema deaths.
Indication: Inflammatory Bowel Disease (UC, CD)
UC: 3.5 months median; CD: 6.3 months median; primary care delay up to 16 months. Women experience twice the delay of men (7.8 vs 3.9 months). 37.9% of UC and 23.4% of CD patients face delays exceeding 12 months. During this time, uncontrolled inflammation drives irreversible bowel damage.
| Market | Addressable Undiagnosed | Net Revenue per Patient | Ada Opportunity (5% capture) |
|---|---|---|---|
| USA | 25,000 - 85,000 | $28,000 - $54,000 / year | $2.8M - $27.5M / year |
| DACH | 12,000 - 35,000 | $32,000 - $55,000 / year | $154K - $1.2M / year |
| Rest of World | 100,000 - 300,000 | $20,000 - $40,000 / year | $8M - $72M / year |
| TOTAL | 137,000 - 420,000 | - | $11M - $101M / year |
"IBD's 16-Month Primary Care Delay Costs Patients Years of Bowel Damage"
Inflammatory bowel disease (IBD) patients wait a median of 16 months in primary care before diagnosis, with women experiencing twice the delay of men (7.8 vs 3.9 months). During this time, uncontrolled inflammation drives irreversible bowel damage, increasing the need for emergency hospitalizations and surgeries. 37.9% of ulcerative colitis patients and 23.4% of Crohn's patients face delays exceeding 12 months.
Ada's symptom assessment identifies the hallmark signs—chronic bloody diarrhea, urgency, abdominal pain—and routes patients directly to gastroenterology with fecal calprotectin pre-screening, bypassing the primary care bottleneck. With ENTYVIO as the #1 prescribed IBD biologic in the US, capturing even 1-5% of the estimated 25,000-85,000 undiagnosed moderate-to-severe IBD patients represents a $2.8M-$27.5M annual US revenue opportunity for Ada at 8-12% finder fees, while preventing years of unnecessary disease progression.
Indication: Eosinophilic Esophagitis (EoE)
Median 1.2-10 years (European cohorts); Swiss 6 years, Danish 10 years; older cohorts up to 12.7 years. Diagnostic delay is THE primary risk factor for esophageal strictures: stricture prevalence increases from 17.2% (0-2 years delay) to 70.8% (>20 years delay).
| Market | Addressable Undiagnosed | Net Revenue per Patient | Ada Opportunity (5% capture) |
|---|---|---|---|
| USA | 40,000 - 115,000 | $9,000 - $13,500 / year* | $1.4M - $9.3M / year |
| DACH | 10,000 - 30,000 | $4,830 - $7,300 / year* | $48K - $274K / year |
| Rest of World | 15,000 - 80,000 | $3,200 - $6,000 / year* | $48K - $480K / year |
| TOTAL | 65,000 - 225,000 | - | $1.5M - $10M / year |
* Assumes off-label repeat 12-week courses; label limits to 12 weeks. If single course only, divide by 4.
"EoE's Decade of Delay: When Dysphagia Becomes Strictures"
Eosinophilic esophagitis (EoE) patients endure a median 2.1 to 10 years of progressive dysphagia—adapting by eating slowly, avoiding solid foods, and living in fear of food impaction—before an esophageal biopsy reveals the eosinophilic inflammation driving their symptoms. Older cohorts experienced delays up to 12.7 years. During this time, untreated inflammation transforms into irreversible esophageal strictures: stricture prevalence climbs from 17.2% at diagnosis within 2 years to 70.8% after 20+ years of delay. Globally, 50-70% of EoE cases remain undiagnosed because endoscopists fail to biopsy normal-appearing esophagi (50% of EoE has no macroscopic findings).
Ada's symptom assessment identifies the hallmark—dysphagia with PPI-refractory heartburn—and explicitly routes patients for upper endoscopy with ≥6 esophageal biopsies (per guidelines). With an estimated 225,000-467,000 undiagnosed EoE patients in the US, of whom 60-70% are Ada-addressable, and EOHILIA capturing 30-40% market share (~40,000-115,000 patients), the Ada Patient Finder opportunity reaches $1.4M-$9.3M in annual US revenue at 5% capture (assuming off-label repeat 12-week courses; 8-12% finder fees)—while preventing the irreversible march from dysphagia to strictures.
Indication: Primary Immunodeficiency (PIDD), CIDP
PIDD: 4-8 years; CIDP: 12-24 months. 70-90% of PIDD cases undiagnosed worldwide. Patients accumulate permanent lung damage (bronchiectasis), chronic GI inflammation, and missed work/school—all preventable with immunoglobulin replacement.
| Addressable Undiagnosed: | 19,000 - 116,000 |
| Net Revenue per Patient: | $50,000 - $135,000 / year (PIDD $40K-$120K; CIDP $60K-$150K) |
| Ada Opportunity (5% capture, USA): | $3.8M - $94.0M / year |
Recommendation: Pursue opportunistically with focus on high-frequency infection pattern (>4 respiratory infections per year in adults); requires partnership with immunology networks.
| Drug | Tier | Fit Score | Why Lower Priority / Not Suitable |
|---|---|---|---|
| NINLARO Multiple myeloma |
Tier 3 | 5/10 | Moderate delays (77-99 days), high revenue ($60K-$120K annually), but nonspecific symptoms (back pain + anemia) limit Ada specificity; competitive MM market; second-line positioning. Ada opportunity: $240K-$3.2M at 5% capture (USA). |
| ADCETRIS Hodgkin lymphoma |
Tier 3 | 4/10 | Low diagnostic delay (3-6 months), minimal underdiagnosis; Ada cannot add value beyond standard-of-care imaging referral; rare cancers with high specialist diagnosis rates are poor fit for primary symptom triage. Ada opportunity: <$1M (USA). |
| LIVTENCITY Post-transplant CMV |
NO | 3/10 | No diagnostic delay (protocol-driven surveillance in transplant centers); no underdiagnosis; Ada cannot add value in specialist-driven setting. CMV diagnosis is asymptomatic viremia detected via lab surveillance, not symptom assessment. |
| QDENGA Dengue vaccine |
NO | 2/10 | Preventive vaccine, not diagnostic therapy; no symptom-based patient identification; vaccine eligibility is geography-based (endemic regions) and age-based (≥4 years), not symptom-driven; traditional finder fee model not applicable to population-level vaccination. |
| ADZYNMA Congenital TTP |
NO | 3/10 | Ultra-rare (<1-2 per million prevalence); estimated US addressable pool <50 patients; minimal undiagnosed pool (most cTTP diagnosed in childhood after acute thrombotic events); total opportunity <$1M. Acute presentation requires emergency care, not primary symptom assessment. |
| VYVANSE ADHD (generic) |
NO | N/A | US patent expired Aug 2023; 14 generics launched; terminal decline; not relevant for Patient Finder. |
| TRINTELLIX Depression |
NO | N/A | Insufficient diagnostic delay data; competitive antidepressant market; symptom overlap (fatigue, anhedonia, sleep disturbance) with other conditions (hypothyroidism, chronic fatigue syndrome, sleep apnea) reduces Ada specificity. Further research needed. |
Immunoglobulin Portfolio (PIDD) — Fit Score 7/10
Very high underdiagnosis (70-90%), long delays (4-8 years), but execution challenge due to symptom overlap with common conditions. US opportunity at 5% capture: $3.8M-$94.0M (wide range due to large undiagnosed pool uncertainty).
Total Addressable Revenue (Tier 1+2, USA, 5% capture): $970M - $14.76B
(Wide range reflects uncertainty in undiagnosed pools; conservative estimate ~$5-8M annually across all four products)